Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roivant
Biotech
Priovant will move brepocitinib to phase 3 after midstage win
Priovant has presented promising results for potential blockbuster brepocitinib in a rare skin disorder, cutaneous sarcoidosis.
Kevin Dunleavy
Feb 6, 2026 7:00am
Roivant reports phase 3 autoimmune win for ex-Pfizer asset
Sep 17, 2025 7:00am
Revised Blueprint-VantAI deal turns focus to molecular glues
May 20, 2025 10:32am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
Immunovant narrows R&D focus as Roivant execs join C-suite
Apr 21, 2025 10:00am
Immunovant posts phase 3 autoimmune win but won't seek approval
Mar 19, 2025 9:15am
